Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.14)
# 2,671
Out of 4,829 analysts
107
Total ratings
43.64%
Success rate
-6.6%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $7.11 | -1.55% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $181.88 | +9.96% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $176.96 | +1.72% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $4.13 | -3.15% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $6.15 | +143.90% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $693.46 | -2.66% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $66.97 | -2.94% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.22 | +6.95% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $245.73 | +7.84% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $15.82 | +26.42% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $140 | $148.22 | -5.55% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $40.01 | -10.02% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $148.99 | +77.86% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $59.19 | -23.97% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $2.89 | +38.41% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $17.59 | +30.76% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $25.02 | -20.06% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $8.20 | +220.12% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $5.12 | +192.97% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.67 | +311.99% | 2 | Jan 4, 2022 |
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $7.11
Upside: -1.55%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $181.88
Upside: +9.96%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $176.96
Upside: +1.72%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $4.13
Upside: -3.15%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $6.15
Upside: +143.90%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $693.46
Upside: -2.66%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $66.97
Upside: -2.94%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.22
Upside: +6.95%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $245.73
Upside: +7.84%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.82
Upside: +26.42%
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $148.22
Upside: -5.55%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $40.01
Upside: -10.02%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $148.99
Upside: +77.86%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $59.19
Upside: -23.97%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $2.89
Upside: +38.41%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $17.59
Upside: +30.76%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $25.02
Upside: -20.06%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $8.20
Upside: +220.12%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $5.12
Upside: +192.97%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.67
Upside: +311.99%